{"entries":[{"caption":"2D skeletal representation of benzene","key":"fig-benzene","order":{"number":1,"section":[7,2,1,0,0,0,0]}},{"caption":"Proposed two-step protocol for outpatient NSAID oral challenge in patients without AERD. Adapted from Li et al. JACI In Practice. 2022","key":"tbl-nsaids","order":{"number":3,"section":[7,6,3,0,0,0,0]}},{"caption":"Characteristics of iron formulations available in the United States","key":"tbl-iv-iron","order":{"number":2,"section":[7,4,1,0,0,0,0]}},{"caption":"Select aromatic and non-aromatic AEDs. Adapted from Mani et al. Seizure. 2019.","key":"tbl-aeds","order":{"number":1,"section":[7,2,1,0,0,0,0]}},{"caption":"Select topical drugs for treatment of atopic dermatitis by propylene glcyol content","key":"tbl-topicals-propylene-glycol","order":{"number":4,"section":[7,8,4,0,0,0,0]}},{"caption":"Select commercially-available eye drops for common treatment categories by benzylalkonium chloride content","key":"tbl-eyedrops-benzalkonium-chloride","order":{"number":5,"section":[7,8,5,0,0,0,0]}}],"headings":["antibiotics","cephalosporins","fluoroquinolones","macrolides","background","skin-testing","oral-challenge","penicillins","background-1","skin-testing-1","sulfa-antibiotics","vancomycin","antiepileptic-drugs","background-2","buproprion","iron","background-3","immediate-hypersensitivity-reactions","minor-infusion-reactions","skin-testing-2","management","references","local-anesthetics","background-4","management-1","nonsteroidal-anti-inflammatory-drugs","background-5","management-2","oral-challenge-1","radiocontrast","background-6","infusion-reactions","immediate-hypersensitivity-reactions-1","delayed-hypersensitivity-reactions","skin-testing-3","intravenous-challenge","management-3","topicals","antibiotics-1","anesthetics","corticosteroids","propylene-glycol","eye-drops","vaccines","background-7","skin-testing-4","management-4"],"options":{"chapters":true}}